WuXi XDC Cayman, Inc. 2268
HKEX · Hong Kong SAR China · Commercial Services
HKD 82.00+3.95 (+5.06%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
WuXi XDC Cayman (SEHK:2268) reported GMP release for key production lines at its new Singapore site in 2026. The Singapore facility GMP release confirms the plant is cleared to produce clinical and commercial batches under regulatory quality standards. WuXi XDC Cayman and Ona Therapeutics agreed an exclusive global out-licensing collaboration that expands their existing partnership. The GMP release in Singapore and the expanded Ona Therapeutics out-licensing deal both need weighing against...
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today held a grand GMP release ceremony for its Singapore manufacturing site at Tuas Biomedical Park. From announcing the new site in March 2024 to achieving GMP release of the BCM3 antibody intermediate and conjugated drug substance dual-function production line and the DP4 facility in August 2026, this important mil
The deal grants Ona Therapeutics rights to develop an ADC targeting a single undisclosed target.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.